The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process.
Meredith B. Buxton
No relevant relationships to disclose
Kelsey Natsuhara
No relevant relationships to disclose
Angela DeMichele
No relevant relationships to disclose
Jane Perlmutter
No relevant relationships to disclose
Nola M Hylton
No relevant relationships to disclose
Douglas Yee
Consultant or Advisory Role - Symphogen
Laura van't Veer
Employment or Leadership Position - Agendia
Stock Ownership - Agendia
William Fraser Symmans
No relevant relationships to disclose
Michael Hogarth
No relevant relationships to disclose
Julia Lyandres
No relevant relationships to disclose
Sarah E Davis
No relevant relationships to disclose
Susan Flynn
No relevant relationships to disclose
Melissa Paoloni
No relevant relationships to disclose
Donald A. Berry
Employment or Leadership Position - Berry Consultants, LLC
Consultant or Advisory Role - Berry Consultants, LLC
Stock Ownership - Berry Consultants, LLC
Laura Esserman
No relevant relationships to disclose